General MedicationsINTRAVENOUSGeneric

EXBLIFEP

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

Standard Dose

EQ 2GM BASE/VIAL;0.5GM/VIAL

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: Discontinued

Summary

Approval overview EXBLIFEP is listed in Drugs@FDA under application 216165 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM Form and strength POWDER;INTRAVENOUS - EQ 2GM BASE/VIAL;0.5GM/VIAL Sponsor ORCHID PHARMA Submission history Latest submission status date: 2024-02-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview EXBLIFEP is listed in Drugs@FDA under application 216165 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM Form and strength POWDER;INTRAVENOUS - EQ 2GM BASE/VIAL;0.5GM/VIAL Sponsor ORCHID PHARMA Submission history Latest submission status date: 2024-02-22 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Discontinued
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.